rs11665748 - KLK15 - KLK3

Magnitude 2.2 · 2 studies on file

Reported associations

  • Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer - Unknown journal (n.d.) · Unknown authors · PubMed 28139693

    ABSTRACT: Prostate-specific antigen (PSA) levels have been used for detection and surveillance of prostate cancer (PCa). However, factors other than PCa-such as genetics-can impact PSA. Here we present findings from a genome-wide association study (GWAS) of PSA in 28,503 Kaiser Permanente whites and 17,428 men from replication cohorts. We detect 40 genome-wide significant (P<5 × 10−8) single-nucleotide polymorphisms (SNPs): 19 novel, 15 previously identified for PSA (14 of which were also PCa-associated), and 6 previously identified for PCa only. Further analysis incorporating PCa cases suggests that at least half of the 40 SNPs are PSA-associated independent of PCa. The 40 SNPs explain 9.5% of PSA variation in non-Hispanic whites, and the remaining GWAS SNPs explain an additional 3

  • Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants - Unknown journal (n.d.) · Unknown authors · PubMed 37945903

    [INTRO] Introduction [INTRO] The transferability and clinical value of genetic risk scores (GRS) across populations remains limited due to an imbalance in genetic studies across ancestrally diverse populations. We conducted a multi-ancestry genome-wide association study (GWAS) of 156,319 prostate cancer cases and 788,443 controls of European, African, Asian, and Hispanic men, reflecting a 57% increase in the number of non-European cases over previous prostate cancer GWAS. We identified 187 novel risk variants for prostate cancer, increasing the total number of risk variants to 451. An externally replicated multi-ancestry GRS was associated with risk that ranged from 1.8 (per standard deviation (SD)) in African ancestry men to 2.2 in European ancestry men. The GRS was associated with a gre


Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Discuss with your doctor

  • prostate cancer risk assessment High

    rs11665748 is associated with prostate cancer risk (odds ratio approximately 1.13); genetic contribution to risk should inform screening strategy

    Discuss personal and family history of prostate cancer; consider timing and frequency of screening

Screening

  • genetic-adjusted PSA screening High

    rs11665748 is strongly associated with baseline PSA; genetic effect should be considered when interpreting PSA values for prostate cancer screening

    Discuss with physician how this genetic variant may affect PSA baseline and screening interpretation